Evidence map›Paper›PMID 24982361›Full record

ArticleAnticancer research2014

Antileukemic activity of Tillandsia recurvata and some of its cycloartanes.

Henry I C Lowe, Ngeh J Toyang, Charah T Watson, Kenneth N N Ayeah, Joseph Bryant

Abstract read
In one paragraph

Article in Anticancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Cytotoxic Fractions fromMolecules (Basel, Switzerland) · 2021
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Henry I C LoweBio-Tech R & D Institute, Kingston, Jamaica Educational and Scientific Corporation, Wellington, FL, U.S.A. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, U.S.A. henrylowe@cwjamaica.com.
Ngeh J ToyangEducational and Scientific Corporation, Wellington, FL, U.S.A. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Charah T WatsonBio-Tech R & D Institute, Kingston, Jamaica.
Kenneth N N AyeahEducational and Scientific Corporation, Wellington, FL, U.S.A. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Joseph BryantInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
NCI NIH HHS P30 CA134274
6 · The paper itself

Abstract

backgroundApproximately 250,000 deaths were caused by leukemia globally in 2012 and about 40%-50% of all leukemia diagnoses end-up in death. Medicinal plants are a rich source for the discovery of new drugs against leukemia and other types of cancers. To this end, we subjected the Jamaican ball moss (Tillandsia recurvata) and its cycloartanes, as well as some analogs, to in vitro screening against a number of leukemia cell lines. The WST-1 anti-proliferation assay was used to determine the anticancer activity of ball moss and two cycloartanes isolated from ball moss and four of their analogs against four leukemia cell lines (HL-60, K562, MOLM-14, monoMac6). Ball moss crude methanolic extract showed activity with a 50% inhibition concentration (IC50) value of 3.028 μg/ml against the Molm-14 cell line but was ineffective against HL-60 cells. The six cycloartanes tested demonstrated varying activity against the four leukemia cancer cell lines with IC50 values ranging from 1.83 μM to 18.3 μM. Five out of the six cycloartanes demonstrated activity, while one was inactive against all four cell lines. The preliminary activity demonstrated by the Jamaican ball moss and its cycloartanes against selected leukemia cell lines continues to throw light on the broad anticancer activity of ball moss. Further studies to evaluate the efficacy of these molecules in other leukemia cell lines are required in order to validate the activity of these molecules, as well as to determine their mechanisms of action and ascertain the activity in vivo in order to establish efficacy and safety profiles.

Indexed as

Cell Line, TumorHL-60 CellsHumansK562 CellsLeukemiaPlant ExtractsTillandsiaTriterpenesPlant ExtractsTriterpenescancerCycloartaneJamaican ball mossleukemia

Identifiers

PMID24982361
PMCPMC4498400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.